Integrated Manufacturing Learn More Developing novel gene and cell therapies Learn More Fostering next-generation gene therapy delivery Learn More Putting advocacy into action Learn More Latest News Nov 12, 2019 Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates View Press Release Oct 21, 2019 Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress View Press Release Oct 15, 2019 Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa View Press Release View All Our inspiration Learn More Pipeline Our clinical-stage therapies are designed to deliver functional copies of affected genes to cells using gene transfer technologies. Explore R&D EB-101 Preparing to enter Phase 3 development in Q4 2019. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-101 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type B (MPS IIIB). Learn More Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
